Glaxo investing $2 billion to expand flu vaccine manufacturing
As a leading provider of vaccines and anti-viral medications, GSK is committed to doing everything we can to support governments, health authorities and our own employees around the world in planning to respond to a global influenza pandemic. We have taken significant steps to prepare for a pandemic including:
Investing over $2 billion to expand our flu vaccine manufacturing capacity and increase production of the anti-viral Relenza; this includes doubling vaccine manufacturing capacity for our Dresden, Germany site, the acquisition of Canadian vaccine maker ID Biomedical, and exploring partnerships with other manufacturers to increase Relenza capacity.
Developing an H5N1 prototype pandemic vaccine. The prototype uses an adjuvant which may boost the body's immune response to the vaccine and allow for lower doses to be used which would be essential for treating large populations in a pandemic. The prototype may also protect against additional strains (drifted from H5N1) that could arise. Clinical trials with the H5N1 flu strain are planned in 2006.
Investigating new vaccine production technologies including cell culture at our newly-acquired Marietta, Pennsylvania, USA facility, and novel - more potent - adjuvants.